NASDAQ:ADMP - Adamis Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $1.25
  • Forecasted Upside: 75.73 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.71
▼ -0.0177 (-2.43%)
1 month | 3 months | 12 months
Get New Adamis Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADMP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADMP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$1.25
▲ +75.73% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Adamis Pharmaceuticals in the last 3 months. The average price target is $1.25, with a high forecast of $1.50 and a low forecast of $1.00. The average price target represents a 75.73% upside from the last price of $0.71.
Hold
The current consensus among 3 polled investment analysts is to hold stock in Adamis Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/27/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/22/2021Maxim GroupReiterated RatingHoldLow
i
11/16/2020Maxim GroupDowngradeBuy ➝ HoldHigh
i
Rating by Jason McCarthy at Maxim Group
9/23/2020Maxim GroupReiterated RatingBuy$1.50High
i
Rating by Jason McCarthy at Maxim Group
8/24/2020Dawson JamesDowngradeBuy ➝ NeutralMedium
i
Rating by J. Kolbert at Dawson James
8/19/2020Raymond JamesReiterated RatingHoldLow
i
6/16/2020Maxim GroupReiterated RatingBuy$1.50Low
i
Rating by Jason McCarthy at Maxim Group
6/15/2020Dawson JamesUpgradeBuy$1.00Medium
i
Rating by Jason Kolbert at Dawson James
5/13/2020Maxim GroupUpgradeHold ➝ Buy$1.50High
i
Rating by Jason McCarthy at Maxim Group
2/27/2020Dawson JamesDowngradeBuy ➝ NeutralHigh
i
Rating by J. Kolbert at Dawson James
11/26/2019Raymond JamesDowngradeOutperform ➝ Market PerformHigh
i
11/25/2019Maxim GroupDowngradeBuy ➝ HoldN/A
i
Rating by Jason McCarthy at Maxim Group
8/9/2019Maxim GroupSet Price TargetBuy$6.00High
i
Rating by Jason McCarthy at Maxim Group
7/23/2019B. RileyUpgradeSell ➝ NeutralLow
i
Rating by A. D'silva at B. Riley
7/16/2019B. RileyDowngradeNeutral ➝ Sell$1.90 ➝ $1.10Low
i
Rating by A. D'silva at B. Riley
7/2/2019Dawson JamesInitiated CoverageBuyMedium
i
Rating by Jason Kolbert at Dawson James
5/10/2019Raymond JamesSet Price TargetBuy$4.00High
i
Rating by Elliot Wilbur at Raymond James
3/19/2019Maxim GroupSet Price TargetBuy$10.00Low
i
Rating by Jason McCarthy at Maxim Group
12/7/2018Maxim GroupSet Price TargetBuy$10.00Low
i
Rating by Jason McCarthy at Maxim Group
11/13/2018HC WainwrightSet Price TargetBuy$7.00Medium
i
Rating by Jason Kolbert at HC Wainwright
11/12/2018B. RileyDowngradeBuy ➝ Neutral$7.50 ➝ $2.50High
i
Rating by A. D'silva at B. Riley
9/28/2018HC WainwrightSet Price TargetBuy$7.00High
i
Rating by Jason Kolbert at HC Wainwright
9/12/2018Maxim GroupReiterated RatingBuy$13.00Low
i
Rating by Jason McCarthy at Maxim Group
9/10/2018HC WainwrightSet Price TargetBuy$7.00Medium
i
Rating by Jason Kolbert at HC Wainwright
8/23/2018HC WainwrightReiterated RatingBuyLow
i
Rating by Jason Kolbert at HC Wainwright
7/3/2018B. RileyBoost Price TargetBuy$7.50High
i
Rating by A. D'silva at B. Riley
7/2/2018Maxim GroupBoost Price TargetBuy$13.00High
i
Rating by Jason McCarthy at Maxim Group
7/2/2018HC WainwrightReiterated RatingBuy$10.00High
i
Rating by Jason Kolbert at HC Wainwright
5/14/2018HC WainwrightSet Price TargetBuy$7.00High
i
Rating by Jason Kolbert at HC Wainwright
5/11/2018Maxim GroupBoost Price TargetBuy ➝ Buy$5.00 ➝ $10.00Low
i
Rating by Jason McCarthy at Maxim Group
4/23/2018HC WainwrightInitiated CoverageBuy$7.00High
i
Rating by J. Kolbert at HC Wainwright
3/23/2018B. RileyBoost Price TargetBuy ➝ Buy$6.25 ➝ $7.50Low
i
Rating by A. D'silva at B. Riley
3/19/2018Maxim GroupSet Price TargetBuy$5.00High
i
Rating by Jason McCarthy at Maxim Group
3/14/2018B. RileyReiterated RatingBuyMedium
i
Rating by Andrew D'silva at B. Riley
3/6/2018Maxim GroupSet Price TargetBuy$5.00High
i
Rating by Jason Kolbert at Maxim Group
2/23/2018Raymond JamesSet Price TargetBuy$7.00High
i
Rating by Elliot Wilbur at Raymond James
2/23/2018Maxim GroupSet Price TargetBuy$5.00High
i
Rating by Jason Kolbert at Maxim Group
2/14/2018Maxim GroupSet Price TargetBuy$5.00Low
i
Rating by Jason Kolbert at Maxim Group
12/5/2017Maxim GroupSet Price TargetBuy ➝ Buy$14.00Medium
i
Rating by Jason Kolbert at Maxim Group
11/30/2017B. RileySet Price TargetBuy$10.00Medium
i
Rating by Andrew D'silva at B. Riley
11/15/2017B. RileySet Price TargetBuy$10.00N/A
i
Rating by Andrew D'silva at B. Riley
10/4/2017B. RileyReiterated RatingBuy ➝ Buy$9.50Low
i
9/12/2017Raymond JamesInitiated CoverageOutperform$7.00High
i
8/21/2017Maxim GroupReiterated RatingBuy$13.00High
i
Rating by Jason Kolbert at Maxim Group
6/12/2017Maxim GroupReiterated RatingBuy$10.00Low
i
Rating by Jason Kolbert at Maxim Group
3/23/2017Maxim GroupReiterated RatingBuy$10.00High
i
Rating by Jason Kolbert at Maxim Group
1/25/2017Maxim GroupReiterated RatingBuy$10.00N/A
i
Rating by Jason Kolbert at Maxim Group
1/24/2017B. RileyReiterated RatingBuy$5.00N/A
i
Rating by G. Chodaczek at B. Riley
1/19/2017B. RileyReiterated RatingBuy$5.00N/A
i
Rating by G. Chodaczek at B. Riley
1/19/2017Maxim GroupSet Price TargetBuy$10.00N/A
i
Rating by Jason Kolbert at Maxim Group
12/24/2016B. RileyInitiated CoverageBuy$5.00N/A
i
Rating by G. Chodaczek at B. Riley
12/20/2016Maxim GroupSet Price TargetBuy$10.00N/A
i
Rating by Jason Kolbert at Maxim Group
12/19/2016B. RileyInitiated CoverageBuy$5.00N/A
i
Rating by G. Chodaczek at B. Riley
10/30/2016Maxim GroupSet Price TargetBuy$10.00N/A
i
Rating by Jason Kolbert at Maxim Group
9/19/2016Maxim GroupSet Price TargetBuy$10.00N/A
i
Rating by jason kolbert at Maxim Group
8/29/2016Maxim GroupReiterated RatingBuy$10.00N/A
i
Rating by Jason Kolbert at Maxim Group
7/21/2016Maxim GroupLower Price TargetBuy$17.00 ➝ $10.00N/A
i
Rating by Jason Kolbert at Maxim Group
6/6/2016Maxim GroupReiterated RatingBuy$17.00N/A
i
Rating by Jason Kolbert at Maxim Group
5/10/2016Maxim GroupReiterated RatingBuyN/A
i
Rating by Jason Kolbert at Maxim Group
(Data available from 4/19/2016 forward)
Adamis Pharmaceuticals logo
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; Tadalafil (APC-8000) for the treatment of erectile dysfunction; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.
Read More

Today's Range

Now: $0.71
$0.69
$0.72

50 Day Range

MA: $0.97
$0.74
$1.13

52 Week Range

Now: $0.71
$0.32
$2.34

Volume

108,080 shs

Average Volume

17,068,859 shs

Market Capitalization

$95.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.68

Frequently Asked Questions

What sell-side analysts currently cover shares of Adamis Pharmaceuticals?

The following equities research analysts have issued research reports on Adamis Pharmaceuticals in the last year: Dawson James, Maxim Group, Raymond James, and Zacks Investment Research.
View the latest analyst ratings for ADMP.

What is the current price target for Adamis Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Adamis Pharmaceuticals in the last year. Their average twelve-month price target is $1.25, suggesting a possible upside of 71.5%. Maxim Group has the highest price target set, predicting ADMP will reach $1.50 in the next twelve months. Dawson James has the lowest price target set, forecasting a price of $1.00 for Adamis Pharmaceuticals in the next year.
View the latest price targets for ADMP.

What is the current consensus analyst rating for Adamis Pharmaceuticals?

Adamis Pharmaceuticals currently has 3 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ADMP, but not buy more shares or sell existing shares.
View the latest ratings for ADMP.

What other companies compete with Adamis Pharmaceuticals?

How do I contact Adamis Pharmaceuticals' investor relations team?

Adamis Pharmaceuticals' physical mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company's listed phone number is 858-997-2400 and its investor relations email address is [email protected] The official website for Adamis Pharmaceuticals is www.adamispharmaceuticals.com.